Thu, 27 Oct 2016 08:00:00 EDTProvided are devices, systems and methods for evaluation of hemostasis. Also provided are sound focusing assemblies.
Thu, 27 Oct 2016 08:00:00 EDTMethods and kits which utilize a conjugate, preferably an adduct, of ergosterol for determining the presence or level of a broad spectrum of ergosterol-containing organisms (e.g., fungi) in various substrates are disclosed. These methods and kits can be used to accurately and efficiently diagnose a subject having a fungal infection, particularly invasive fungal infection, and to accurately and efficiently detect the presence of fungi and other ergosterol-containing organisms in other substrates. Antibodies and other compounds (e.g., molecularly imprinted polymers) that are capable of selectively binding to ergosterol or to an ergosterol-containing conjugate and methods of producing same are also disclosed.
Thu, 27 Oct 2016 08:00:00 EDTThe emergence of mutations in tyrosine kinases following treatment of cancer patients with molecular-targeted therapy represents a major mechanism of acquired drug resistance. Here, we describe a mutation in the serpentine receptor, Smoothened (SMO), which results in resistance to a Hedgehog (Hh) pathway inhibitor in medulloblastoma. A single amino acid substitution in a conserved aspartic acid residue of SMO maintains Hh signaling, but results in the inability of the Hh pathway inhibitor, GDC-0449, to bind SMO and suppress the pathway. This mutation was not only acquired in a GDC-0449-resistant mouse model of medulloblastoma, but was identified in a Medulloblastoma patient following relapse on GDC-0449. The invention provides screening methods to detect SMO mutations and methods to screen for drugs that specifically modulate mutant SMO exhibiting drug resistance.
Thu, 27 Oct 2016 08:00:00 EDTThe invention generally relates to methods for the diagnosis and treatment of neurological and neurodegenerative diseases, disorders, and associated processes. Specifically, the present invention is directed toward methods to determine prognosis, diagnosis or efficacy of a therapeutic regimen by using a detectable label to measure levels of alpha-synuclein.
Thu, 27 Oct 2016 08:00:00 EDTMethods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting lectin binding on proteins in biological fluids, and comparing the detected lectin binding with reference values for the binding of lectin of such proteins in healthy or disease states.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention provides a method and a reagent for measuring periostin contained in a sample with improved accuracy, a method for improving accuracy in measurement of periostin, and a method of testing for pulmonary fibrosis or interstitial pneumonia with improved accuracy. The antibody of the present invention binds to at least one region selected from the group consisting of an EMI region, an R1 region, an R2 region, and an R3 region of periostin or a cleavage product thereof. The method and the reagent for measuring periostin and the method for improving accuracy in periostin measurement of the present invention is characterized by detecting at least one region selected from the group consisting of an EMI region, an R1 region, an R2 region, and an R3 region of periostin. The method of testing for pulmonary fibrosis or interstitial pneumonia of the present invention includes the steps of a) measuring the amount or concentration of periostin in a sample derived from a subject, which measuring includes detecting at least one region selected from the group consisting of an EMI region, an R1 region, an R2 region, and an R3 region of periostin and b) comparing the amount or concentration of the periostin in the sample derived from the subject with an amount or concentration of periostin in a sample derived from a living body not suffering from pulmonary fibrosis and interstitial pneumonia.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Trefoil factor 3 as diagnostic and prognostic biomarker assays in renal injuries.
Thu, 27 Oct 2016 08:00:00 EDTMethods, kits, and diagnostic devices are disclosed for diagnosing an invasive fungal infection in a subject by measuring a T-cell interferon gamma (IFN-γ) response after exposure to a fungal antigen.
Thu, 27 Oct 2016 08:00:00 EDTSpecific peptides, and derived ionization characteristics of those peptides from Death Receptor 5 (DRS) protein are provided that are particularly advantageous for quantifying the DRS protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from a biological sample using the Liquid Tissue™ reagents and protocol, and the DRS protein are quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described for one or more of the DRS protein. These peptides can be quantitated if they reside in a modified or in an unmodified form. An example of a modified form of a DRS peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence
Thu, 27 Oct 2016 08:00:00 EDTA vertical flow membrane assay device for quantitative determination of an analyte in a sample comprising at least a porous membrane and binding molecules attached to colored particles suspended in a buffer, wherein said porous membrane has an average pore size of about 2 μm to about 6 μm, said colored particles have an average diameter in the interval of 80 nm to about 400 nm, and said buffer has a pH in the interval of 7.5 to 1 l. A method for performing a vertical flow membrane assay using a device as disclosed, and/or performing the corresponding method steps.
Thu, 27 Oct 2016 08:00:00 EDTA method of analyzing diagnostic information, the method including: measuring a concentration of a mucin-1 (Tn-MUC1), which is reactive with a lectin that recognizes and binds to an N-acetyl-D-galactosamine→serine (threonine) residue, in a blood sample originated from a subject to be diagnosed; comparing the measured value with a threshold value; and estimating that a disease affecting the subject to be diagnosed is not prostate cancer but a benign prostate disease when the measured value of the concentration of Tn-MUC1 is greater than the threshold value.
Thu, 27 Oct 2016 08:00:00 EDTMethods and kits for the prognosis of breast cancer comprising measurement of nuclear Ep-ICD poly-peptides are provided. Measurement may be quantitative and/or qualitative. The invention also provides a system for generating an Ep-ICD Subcellular Localization Index (ESLI) value, which may be used to prognose breast cancer in a subject.
Thu, 27 Oct 2016 08:00:00 EDTSome embodiments provide for a diagnostic test strip for detecting analytes that contains a carrier strip and one or more test pads. Such test pads contain at least one, but preferably two or three transparent membranes or test pad layers. A first transparent membrane has at least one test reagent that indicates the presence of a reference analyte if it has been stored at or below a specified temperature and at least one test reagent that indicates the presence of a reference analyte if it has received a sufficient volume of body fluid. The second transparent membrane contains at least one test reagent that indicates the presence of at least one hepatitis related target analyte. Test reagents are arranged on the membranes such that analyte detection produces a signal in any desired shape, such as a circle, oval, square, plus sign, an “X” sign, and/or a checkmark. Furthermore, a single membrane may contain two or more separate test reagents that detect the same or different analytes.
Thu, 27 Oct 2016 08:00:00 EDTThe invention relates to a method of identifying a specific fungal species in patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the fungal species from the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the fungal species, and specifically identifying the fungal species. The invention also relates to a method of identifying a mycotoxin in patient tissue or body fluid. The method comprises the steps of extracting and recovering the mycotoxin from the patient tissue or body fluid, contacting the mycotoxin with an antibody directed against the mycotoxin, and identifying the myocotoxin. Both of these methods can be used to determine if a patient is at risk for or has developed a disease state related to a fungal infection, and to develop an effective treatment regimen for the patient.
Thu, 27 Oct 2016 08:00:00 EDTThe object is to provide a lysis method and lysis treatment solution for efficiently lysing cells of various Streptococcus bacteria in milk of a livestock animal to release a specific antigen substance contained in the cells for detecting whether causative bacterium of mastitis is a Streptococcus bacterium or not by using the milk, as well as a detection method using an immunochromatographic device. There is provided a method for lysing a Streptococcus bacterium, which comprises the step of mixing a lysis agent containing a lytic enzyme with milk obtained form a livestock animal to lyse a Streptococcus bacterium existing in the milk. The lytic enzyme is preferably at least one selected from the group consisting of lysozyme, labiase, and β-N-acetylglucosaminidase.
Thu, 27 Oct 2016 08:00:00 EDTThe object is to provide a lysis method, lysis treatment solution, detection method using an immunochromatographic device, and detection kit comprising an immunochromatographic device for detecting whether causative bacterium of mastitis is a staphylococcus or not by using milk of a livestock animal. There is provided a method for lysing a staphylococcus, which comprises the step of mixing a lysis agent containing a lytic enzyme, and at least one kind of ampholytic surfactant, and preferably further containing at least one kind of nonionic surfactant, with milk obtained form a livestock animal to lyse a staphylococcus existing in the milk. The lytic enzyme is preferably lysostaphin.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention relates, e.g., to a composition comprising peptides represented by SEQ ID NO:1, or active variants thereof, wherein the peptides or active variants can bind specifically to an antibody induced by a causative agent of Lyme disease (a pathogenic Borrelia), e.g. in a sample from a subject having Lyme disease. Compositions of the invention may comprise multiple peptides, from multiple proteins. Diagnostic kits comprising the peptides are described, as are diagnostic assays using the peptides.
Thu, 27 Oct 2016 08:00:00 EDTA test element for an assay includes: a cartridge having a housing which includes a priming pad capable of containing a liquid fluid, a wash port having an opening in the housing, and an opening for directly or indirectly applying a sample; and an assay device positioned within the cartridge in fluid communication with the wash port containing an analytical reagent.
Thu, 27 Oct 2016 08:00:00 EDTSome embodiments provide for a diagnostic test strip having a carrier strip that contains a region with one or more test pads in contact with the carrier strip and another region that has one or more memory devices in contact with the carrier strip. The one or more memory devices have connecter pins in contact with the carrier strip and they are optionally in electrical contact with each other when more than one memory device is utilized. Other embodiments provide for a method of detecting one or more analytes in a sample, the method involving contacting an embodiment of a diagnostic test strip with a sample such that the sample contacts the one or more test pads of the diagnostic test strip, and reading the results from the test strip.
Thu, 27 Oct 2016 08:00:00 EDTSome embodiments of the disclosure provide a diagnostic test strip for detecting analytes on one or more test pad using one or more reagents. The diagnostic test strip may include a supporting strip having one or more indentations and one or more test pads having one or more perforated edges. The one or more test pads can be secured to the supporting strip by placing the one or more test pads on the supporting strips and extending at least a portion of the perforated edges of the test pads into the indentations of the supporting strip.
Thu, 27 Oct 2016 08:00:00 EDTSome embodiments of the disclosure provide a diagnostic assay test strip for detecting analytes on one or more test pad using one or more reagents. The diagnostic test strip may include a supporting strip having one or more indentations and one or more test pads capable of fitting in those indentations. The diagnostic test strip may include one or more test pads on one or more sides of a carrier strip. The diagnostic test strip may include one or more intermediate layers and a carrier layer and a bottom laminate layer where the test pads are interspersed on the carrier layer. The diagnostic test strip may include test pads with a top, bottom, and sides, where the top and bottom of the pads have a trailing edge and a leading edge that are mechanically fixed to the carrier strip.
Thu, 27 Oct 2016 08:00:00 EDTAn influenza detector for detecting a targeted influenza virus and a surface acoustic wave (SAW) sensor for Influenza A virus detection in liquid are provided. The influenza detector includes a liquid environment, the surface acoustic wave (SAW) sensor and an influenza specific binding agent such as an antibody. The agent is immobilized on a surface of the SAW sensor for selectively capturing an analyte for the targeted influenza virus. The SAW sensor is in contact with the liquid environment and includes a substrate comprising a piezo-electric material for producing a surface acoustic wave signal in response to an applied electric field and an insulative layer formed on top of the substrate and having a functionalized surface formed thereon for selectively immobilizing the influenza specific binding agent, the functionalized surface being in contact with the liquid environment. The surface acoustic wave signal produced by the SAW sensor changes in response to the analyte for the targeted influenza virus being present in the liquid environment and being captured by the influenza specific binding agent immobilized on the functionalized surface of the insulative layer of the SAW sensor.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention deals with a novel method for determining the amount of an analyte in a sample comprising an initial purification step, occurring in a first container, comprising the following steps of mixing the sample, a delipidation agent and magnetic particles coated with first analyte binding partners in the first container, incubating the mix, removing the unbound reagents from the mix, and eluting the bound analyte in an elution solution; a transferring step consisting transferring in a volume of the elution solution comprising the analyte from the first container to a second container; and a quantification step, occurring in the second container, consisting of quantifying the analyte in said elution solution.
Thu, 27 Oct 2016 08:00:00 EDTFluorescent dyes with affinity for nucleic acids and related methods are provided. Dielectric or semiconducting films including fluorescent dyes with affinity for nucleic acids and related methods are also provided. Coumarin-based surfactants conjugated to the fluorescent dyes with affinity for nucleic acids and related methods are provided.
Thu, 27 Oct 2016 08:00:00 EDTMethods and reagents are disclosed for minimizing a false result in an assay measurement for determining a concentration of an analyte in a sample suspected of containing the analyte. The method comprises pretreating both an antibody and a sample to be subjected to a non-agglutination immunoassay. In the method the antibody and the sample are combined with a pretreatment agent selected from the group consisting of hydroxyphenyl-substituted C1-C5 carboxylic acids and metallic salts thereof and halogen-substituted C1-C5 carboxylic acids and metallic salts thereof in an amount effective to enhance the accuracy of the non-agglutination immunoassay.
Thu, 27 Oct 2016 08:00:00 EDTSome embodiments provide for a diagnostic test strip for detecting analytes having an active reference zone that contains a carrier strip and one or more test pads. Such test pads contain at least one, but preferably two transparent membranes or test pad layers. A first transparent membrane has a test reagent that indicates the presence of at least one reference analyte, while a second transparent membrane has a test reagent that indicates the presence of at least one target analyte. Test reagents are arranged on the membranes such that analyte detection produces a signal in any desired shape, such as a circle, oval, square, plus sign, an “X” sign, and/or a checkmark. Furthermore, a single membrane may contain two or more separate test reagents that detect the same or different analytes. Other embodiments provide for a method of detecting one or more analytes in a patient sample.
Thu, 27 Oct 2016 08:00:00 EDTSome embodiments provide for a diagnostic test strip comprising a) a carrier strip with one or more sets of perforations; and b) one or more test pads with a plurality of legs that are attached to and extend away from the pad, wherein the sets of perforations are configured to accept the plurality of legs on each of the test pads. Other embodiments provide for a method for detecting one or more analytes in a patient sample, comprising a) contacting an embodiment of a diagnostic test strip with a patient sample so that the sample contacts the one or more test pads; and b) reading the results from the test strip.
Thu, 27 Oct 2016 08:00:00 EDTSome embodiments provide for a diagnostic test strip having a carrier strip, one or more test pads, and one or more boundary projections which have an opening such that the boundary projections substantially surrounds three sides of each of the one or more test pads. Other embodiments provide for a method of detecting analytes in a patient sample, the method involving contacting an embodiment of a diagnostic test strip with a patient's tongue such that the tongue contacts one or more test pads and reading the results of the analysis from the diagnostic test strip.
Thu, 27 Oct 2016 08:00:00 EDTMethods of prohibiting Xist-dependent silencing of X chromosome genes include targeting the required Xist silencing complex components including SHARP, SMRT, HDAC3, SAF-A, LBR, and the respective binding sites of SHARP, LBR, and SAF-A on Xist, thereby prohibiting Xist repression, allowing for reactivation of the silenced X chromosome genes.
Thu, 27 Oct 2016 08:00:00 EDTAn object of the present invention is to provide a biocompatible liquid that is more essential and practical, and a method for screening the same. The object is achieved by using, as the biocompatible liquid, a liquid having a Hansen solubility parameter (HSP) compatible to a cell to which the liquid is applied.
Thu, 27 Oct 2016 08:00:00 EDTA method for determining sensitivity of a tumor to a HSP90 inhibitor, including: measuring a phosphorylation level of Akt or a phosphorylation level of ERK in a tissue of the tumor from a patient.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention provides systems, devices, kits, and methods for separating blood plasma or serum from whole blood. The present invention further provides systems, devices, and methods for separating a volume of blood plasma or serum from whole blood.
Thu, 27 Oct 2016 08:00:00 EDTMethods and systems for measuring and using the oxidation-reduction potential (ORP) of a biological sample are provided. Also provided are methods of characterizing an individual who has suffered a stroke by measuring the ORP of a biological sample. The disclosed methods can be used to characterize the individual with regard to their likelihood of survival, severity of the stroke and their estimated length of stay in a medical facility.
Thu, 27 Oct 2016 08:00:00 EDTDisclosed herein is a method of generating a high resolution image of a cellular sample, the method including i) labeling a cellular sample with at least one mass tag, thereby producing a labeled sample in which a biological feature of interest is associated with the at least one mass tag, ii) scanning the sample with a continuous or near-continuous primary ion beam to generate sputtered secondary ions and sputtered neutral species, iii) photoionizing the sputtered neutrals to generate ionized neutral species, wherein the sputtered neutrals are photoionized at a site that is proximal to their source on the sample, iv) detecting the ionized neutral species by mass spectrometry, thereby obtaining spatially addressed measurements of the abundance of the at least one mass tag across an area of the sample, and v) producing an image of the sample using the measurements. A system for performing the method is also provided.
Thu, 27 Oct 2016 08:00:00 EDTA method of fabricating polymer single nanowires, comprising the steps of: spin coating a polymethylmethacrylate resist onto a silicon wafer patterned with at least one gold electrode pair; creating a nanochannel using e-beam lithography between each pair of the at least one gold electrode pairs; placing the silicon wafer into an aniline monomer polymerization solution; reacting the polymerization solution to give a coated wafer and a polyaniline film; and cleaning the coated wafer of polymethylmethacrylate resist and polyaniline film to give at least one gold electrode pair with a connecting polymer single nanowire.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention relates to electronic readers configured to perform optical measurements (e.g., absorbance, fluorescence, luminescence, colorimetric analysis, etc.) on samples present on porous matrices. The electronic readers are particularly useful for measuring paper-based devices.
Thu, 27 Oct 2016 08:00:00 EDTThe disclosed technology brings histopathology into the operating theatre, to enable real-time intra-operative digital pathology. The disclosed technology utilizes confocal imaging devices image, in the operating theatre, “optical slices” of fresh tissue—without the need to physically slice and otherwise process the resected tissue as required by frozen section analysis (FSA). The disclosed technology, in certain embodiments, includes a simple, operating-table-side digital histology scanner, with the capability of rapidly scanning all outer margins of a tissue sample (e.g., resection lump, removed tissue mass). Using point-scanning microscopy technology, the disclosed technology, in certain embodiments, precisely scans a thin “optical section” of the resected tissue, and sends the digital image to a pathologist rather than the real tissue, thereby providing the pathologist with the opportunity to analyze the tissue intra-operatively. Thus, the disclosed technology provides digital images with similar information content as FSA, but faster and without destroying the tissue sample itself.
Thu, 27 Oct 2016 08:00:00 EDTThe invention relates to a non-destructive and non-invasive method for determining the concentration or other parameters of constituent substances in fluids, which method is capable of minimizing the optical interfering influences, which are unknown but constant during the individual measurement, of the vessel wall on the measurement result or the evaluation, in that measurements are carried out with different through-radiation path lengths and quotient calculations eliminate the influences of the vessel wall. Wide-area illumination and detection ensure that non-linearities occurring during said measurements do not interfere with the accuracies of the determination.
Thu, 27 Oct 2016 08:00:00 EDTAn image cytometer for capturing and analyzing the image of a sample in the momentum domain. The cytometer is provided with a light source for illuminating a sample with a light beam, an optical transforming system positioned behind the sample in the beam propagation direction for generating the Fourier transform in the space plane, a light sensor array and a spatially selective filter positioned with respect to the optical system such that the Fourier transform is imaged onto the light sensor array.
Thu, 27 Oct 2016 08:00:00 EDTA microorganism evaluation system comprising a viewing section for image acquisition, the viewing section comprising a viewing port configured to accommodate a fluid flow, at least one independently controlled imaging light source operably installed in the viewing section and configured to selectively illuminate the viewing port, and at least one independently controlled light stimulation device operably installed in the viewing section and configured to selectively emit light for invoking a motile response in a microorganism within the fluid flow in the viewing port, whereby the system synchronizes illumination of the at least one imaging light source and the at least one light stimulation device of the viewing section.
Thu, 27 Oct 2016 08:00:00 EDTA stain-barrier is described along with methods of its application to a fabric. The stain barrier can be applied to fabric samples and limits the amount of fabric with which deposited liquid is able to interact. This stain barrier reduces unwanted variability between samples of different dilution or fabric type so that limits of stain detection can be assigned more accurately and precisely and stain detection techniques can be transparently compared.
Thu, 27 Oct 2016 08:00:00 EDTThis specification describes a process of producing a monomeric sugar stream ligno-cellulosic biomass without enzymes or acid catalysts. This is accomplished by removing the water soluble C5 sugars from the ligno-cellulosic biomass feedstream, lowering the pH of the C5 solution with little or no addition of an acid, thermally treating the remaining ligno-cellulosic biomass, combining the thermally treated ligno-cellulosic biomass with the low pH C5 solution and then exposing the mixture to an elevated temperature greater than 80° C. for a time sufficient to hydrolyze at least some of the components of the ligno-cellulosic biomass. Preferably, the thermally treated ligno-cellulosic biomass is subjected to a fiber shives reduction step to reduce the amount of long fiber shives.
Thu, 27 Oct 2016 08:00:00 EDTThe disclosure relates to genetic engineered bacteria having a genetic memory circuit, compositions thereof, formulations thereof, methods of analyses and method of treatment of conditions related to the gastrointestinal tract including the mouth and the stomach.
Thu, 27 Oct 2016 08:00:00 EDTThe invention is directed to methods of assessing the safety of therapeutic compounds and therapeutic genetic manipulations, including integrating gene therapy vectors and genome editing. In particular, the invention provides a method, wherein the oncogenic potential of therapeutic compounds and therapeutic genetic manipulations, including integrating gene therapy vectors and genome editing, is determined by determining the percentage of differentiation blocked hematopoietic progenitor cells.
Thu, 27 Oct 2016 08:00:00 EDTThe present invention provides synthetic DNA strands that find use as controls or in nucleic acid testing methods. In particular, provided herein are synthetic DNA strands of known composition for use as control molecules in stool DNA testing, e.g., of mutations and/or methylation of DNA isolated from stool samples.
Thu, 27 Oct 2016 08:00:00 EDTThe described invention relates to the identification of biomarkers for gastrointestinal diseases and provides methods utilizing the biomarkers for in drug discovery, monitoring of treatment efficacy, and diagnostics. The invention further provides methods for identifying a therapeutic target to treat ulcerative colitis, colorectal cancer, and Crohn's disease.
Thu, 27 Oct 2016 08:00:00 EDTParticular aspects provide novel methods and compositions (e.g., nucleic acids, kits, etc.) having substantial utility for providing a prognosis of prostate cell proliferative disorders. In particular aspects, this is achieved by the analysis of the expression status of a panel of genes, or subsets thereof.
Thu, 27 Oct 2016 08:00:00 EDTA method for testing for target Mycobacteria in a reaction mixture comprising the steps of: providing a reaction mixture; admixing a bacteriophage with the reaction mixture under conditions suitable to allow the bacteriophage to infect any target Mycobacteria present in the reaction mixture; allowing time for the bacteriophage to lyse infected live target Mycobacteria; and analysing in said reaction mixture DNA from the lysed Mycobacteria to identify a signature DNA sequence that occurs in the target Mycobacteriumspedes.
Thu, 27 Oct 2016 08:00:00 EDTThe invention relates to a method of preparing a reaction mixture for Polymerase Chain Reaction (PCR) assay and a solution set for PCR. The method comprises providing a sample solution comprising a biological sample to be amplified in said PCR assay and first colorant providing the solution a first color, providing a reagent solution comprising at least one other substance required for performing said assay and second colorant providing the solution a second color different from the first color, and mixing the sample solution and the first reagent solution for providing a mixed solution to be subjected to the PCR process, the mixed solution having, due to said first and second colorants, a third color different from the first and second colors. The invention significantly aids in pipetting PCR assays.
Thu, 27 Oct 2016 08:00:00 EDTProvided herein is technology relating to automated capture and purify nucleic acids from biological samples. In particular, the technology relates to methods for automated capturing, enriching, and purifying multiple nucleic acid targets from human stool samples.